Early diagnostic value of methylation in promoter region of FAM19A4, PAX1 and miRNA124-2 in cervical lesions

Ya LI; Hui LIU; Jingjing REN; Xiaofu LI; Yanfang ZHI

doi:10.19401/j.cnki.1007-3639.2024.08.003

您当前的位置：

首页 >

文章列表页 >

Early diagnostic value of methylation in promoter region of FAM19A4, PAX1 and miRNA124-2 in cervical lesions

Article | 更新时间：2025-12-31

- Early diagnostic value of methylation in promoter region of FAM19A4, PAX1 and miRNA124-2 in cervical lesions
- China Oncology Vol. 34, Issue 8, Pages: 734-744(2024)
- 作者机构：
  
  郑州大学第三附属医院输血科，河南郑州 450052
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2024.08.003
  CLC： R737.33
- Received：16 January 2024，
  
  Revised：2024-04-16，
  
  Published：30 August 2024
- 稿件说明：
移动端阅览
Ya LI, Hui LIU, Jingjing REN, et al. Early diagnostic value of methylation in promoter region of FAM19A4, PAX1 and miRNA124-2 in cervical lesions[J]. China Oncology, 2024, 34(8): 734-744.
DOI：

Ya LI, Hui LIU, Jingjing REN, et al. Early diagnostic value of methylation in promoter region of FAM19A4, PAX1 and miRNA124-2 in cervical lesions[J]. China Oncology, 2024, 34(8): 734-744. DOI： 10.19401/j.cnki.1007-3639.2024.08.003.

摘要

背景与目的：

目前有关宫颈病变的DNA甲基化研究较多，但DNA甲基化作为宫颈病变的诊断及分流指标在临床实践中的报道较少。本研究拟探讨

FAM

4、

PAX

1及miRNA124-2基因启动子区甲基化在宫颈病变进展中早期诊断的价值。

方法：

收集2020年3月—2022年3月在郑州大学第三附属医院同时行宫颈液基细胞学（thinprep cytologic test，TCT）和HPV检测的患者的宫颈细胞学标本共129例，采用甲基化特异性PCR（methylation-speci

fic PCR，MSP）检测不同宫颈病变中

FAM

4、

PAX

1及miRNA124-2基因启动子区甲基化改变情况，采用受试者工作特征（receiver operating characteristic，ROC）曲线评估3个基因甲基化改变对宫颈病变的诊断价值。本研究经郑州大学第三附属医院伦理委员会批准（伦理审批编号：2023-135-01）。

结果：

根据病理学检查结果分为4组：未见上皮内病变或恶性细胞（no intraepithelial lesions or malignant lesions，NILM）组（42例）、低度鳞状上皮内病变（low grade squamous intraepithelial lesion，LSIL）组（28例）、高度鳞状上皮内病变（high grade squamous intraepithelial lesion，HSIL）组（36例）和鳞癌（squamous cervical cancer，SCC）组（23例）。随宫颈病变级别的增加，

FAM

4、

PAX

1及miRNA124-2基因甲基化检出率逐步增高，差异有统计学意义（

均

0.05）。在HSIL组

FAM

4、

PAX

1、miRNA124-2甲基化检出率分别为81.2%、80.5%和71.8%，在SCC组3种基因甲基化检出率均高达100.0%；细胞学诊断宫颈癌的ROC曲线下面积（area under curve，AUC）为0.731，诊断灵敏度和特异度分别为65.9%和80.4%；

FAM

4、

PAX

1及miRNA124-2基因单独诊断HSIL+（HSIL和SCC）时，

PAX

1甲基化诊断HSIL+的效能最高，AUC为0.925，灵敏度为92.8%，特异度为87.3%；两两联合诊断时，

FAM

4与

PAX

1联合诊断HSIL+的AUC为0.930，灵敏度为95.7%，特异度为87.1%；

FAM

4与miRNA124-2联合诊断HSIL+，AUC为0.895，灵敏度为97.6%，特异度为85.7%；

PAX

1联合miRNA124-2诊断HSIL+，AUC为0.928，灵敏度为95.7%，特异度为89.1%；

PAX

1、

FAM

4及miRNA124-2基因甲基化联合诊断HSIL+，AUC为0.928，灵敏度为100.0%，特异度为81.8%。

结论：

FAM

4、

PAX

1及miRNA124-2基因启动子区甲基化诊断宫颈病变具有较高的灵敏度和特异度，有潜力成为宫颈病变早期诊断的新指标。

Abstract

Background and purpose:

At present

there have been many reports on the study of methylation in cervical lesions

however it is still not clinically practical as a diagnostic and shunting index of cervical lesions. In this study

we intended to investigate the early diagnostic value of

FAM

PAX

1 and miRNA124-2 methylation in promoter region in the progression

of cervical lesions.

Methods:

A total of 129 liquid-based cytology specimens of different grades of cervical lesions diagnosed in the Third Affiliated Hospital of Zhengzhou University from Mar. 2020 to Mar. 2022. Methylation specific PCR (MSP) was used to detect the methylation changes of

FAM

PAX

1 and miRNA124-2 genes in different cervical lesions. Receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of methylation changes of the three genes in cervical lesions. This study was approved by the Ethics Committee of the Third Affiliated Hospital of Zhengzhou University (No. 2023-135-01).

Results:

All the specimens were collected and divided into 4 groups according to the histological results: 42 cases of no intraepithelial lesions or malignant lesions (NILM)

28 cases of low grade squamous intraepithelial lesion (LSIL)

36 cases of high grade squamous intraepithelial lesion (HSIL)

23 cases of squamous cervical cancer (SCC). With the increase in the level of cervical lesions

FAM

PAX

1 and miRNA124-2 gene methylation detection rates increased gradually

and the differences were statistically significant (

0.05). The methylation detection rates of

FAM

PAX

1 and miRNA124-2 in HSIL group were 81.2%

80.5% and 71.8%

respectively

and the methylation detection rates of three genes in SCC group were up to 100.0%. Cytological diagnosis of cervical cancer showed the area under curve (AUC) was 0.731

with a sensitivity and a specificity of 65.9% and 80.4%

respectively. When

FAM

PAX

1 and miRNA124-2 were used alone to diagnose HSIL+ (HSIL and SCC)

PAX

1 methylation had the highest diagnostic efficiency

and the AUC was 0.925

with a sensitivity and a specificity of 92.8% and 87.3%. When the diagnosis was made i

n pairs

the AUC of

FAM

4 combined with

PAX

1 in the diagnosis of HSIL+ was 0.930

with a sensitivity and a specificity of 95.7% and 87.1%

respectively. The AUC of

FAM

4 combined with miRNA124-2 in the diagnosis of HSIL+ was 0.895

with a sensitivity and a specificity of 97.6% and 85.7%

respectively. The AUC of

PAX

1 combined with miRNA124-2 in the diagnosis of HSIL+ was 0.928

with a sensitivity and a specificity of 95.7% and 89.1%

respectively. When the

PAX

1 and

FAM

4 combined with miRNA124-2 in the diagnosis of HSIL+

the AUC was 0.928

with a sensitivity and a specificity of 100.0% and 81.8%

respectively.

Conclusion:

The methylation of the promoter regions of the

FAM

PAX

1 and miRNA124-2 genes demonstrates high sensitivity and specificity in diagnosing cervical lesions

indicating the potential for becoming novel indicators for early diagnosis of cervical lesions.

关键词

Keywords

references

TORRES-ROMAN J S , RONCEROS-CARDENAS L , VALCARCEL B , et al . Cervical cancer mortality among young women in Latin America and the Caribbean: trend analysis from 1997 to 2030 [J ] . BMC Public Health , 2022 , 22 ( 1 ): 113.

BUSKWOFIE A , DAVID-WEST G , CLARE C A . A review of cervical cancer: incidence and disparities [J ] . J Natl Med Assoc , 2020 , 112 ( 2 ): 229 - 232 . DOI: S0027-9684(20)30043-2 http://doi.org/S0027-9684(20)30043-2

LI B H , ZHANG L , ZHAO J G , et al . The value of cytokine levels in triage and risk prediction for women with persistent high-risk human papilloma virus infection of the cervix [J ] . Infect Agent Cancer , 2019 , 14 : 16 .

EL ALIANI A , EL-ABID H , EL MALLALI Y , et al . Association between gene promoter methylation and cervical cancer development: global distribution and a meta-analysis [J ] . Cancer Epidemiol Biomarkers Prev , 2021 , 30 ( 3 ): 450 - 459 .

LIANG L A , EINZMANN T , FRANZEN A , et al . Cervical cancer screening: comparison of conventional pap smear test, liquid-based cytology, and human papillomavirus testing as stand-alone or cotesting strategies [J ] . Cancer Epidemiol Biomarkers Prev , 2021 , 30 ( 3 ): 474 - 484 .

JI W T , LOU W H , HONG Z B , et al . Genomic amplification of HPV, h-TERC and c-MYC in liquid-based cytological specimens for screening of cervical intraepithelial neoplasia and cancer [J ] . Oncol Lett , 2019 , 17 ( 2 ): 2099 - 2106 . DOI: 10.3892/ol.2018.9825 http://doi.org/10.3892/ol.2018.9825

VILLANUEVA L , ÁLVAREZ-ERRICO D , ESTELLER M . The contribution of epigenetics to cancer immunotherapy [J ] . Trends Immunol , 2020 , 41 ( 8 ): 676 - 691 . DOI: S1471-4906(20)30126-5 http://doi.org/S1471-4906(20)30126-5

HAINES K , XU F , VAN ARSDALE A , et al . Investigation of perturbation of DNMT and TET enzymes in endometrial cancer (308) [J ] . Gynecol Oncol , 2022 , 166 : S161 -S162.

KELLY H , BENAVENTE Y , PAVON M A , et al . Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis [J ] . Br J Cancer , 2019 , 121 ( 11 ): 954 - 965 .

FANG C , WANG S Y , LIOU Y L , et al . The promising role of PAX 1 (aliases: HUP48, OFC2) gene methylation in cancer screening [J ] . Mol Genet Genomic Med , 2019 , 7 ( 3 ): e506.

CHENG S J , CHANG C F , KO H H , et al . Hypermethylated ZNF 582 and PAX 1 genes in oral scrapings collected from cancer-adjacent normal oral mucosal sites are associated with aggressive progression and poor prognosis of oral cancer [J ] . Oral Oncol , 2017 , 75 : 169 - 177 .

SMOLARZ B , DURCZYŃSKI A , ROMANOWICZ H , et al . The role of microRNA in pancreatic cancer [J ] . Biomedicines , 2021 , 9 ( 10 ): 1322.

The clinical application value of FAM19A4/mir124-2 methy lation test in hrHPV-positive women [J ] . Cancer Cell Res , 2022 , 9 ( 33 ).

KUMAR R , PAUL A M , RAMESHWAR P , et al . Epigenetic dysregulation at the crossroad of women’s cancer [J ] . Cancers , 2019 , 11 ( 8 ): 1193.

XU W X , XU M Y , WANG L L , et al . Integrative analysis of DNA methylation and gene expression identified cervical cancer-specific diagnostic biomarkers [J ] . Signal Transduct Target Ther , 2019 , 4 : 55 .

GUO M Z , PENG Y J , GAO A A , et al . Epigenetic heterogeneity in cancer [J ] . Biomark Res , 2019 , 7 : 23 . DOI: 10.1186/s40364-019-0174-y http://doi.org/10.1186/s40364-019-0174-y

LI N , HU Y J , ZHANG X Y , et al . DNA methylation markers as triage test for the early identification of cervical lesions in a Chinese population [J ] . Int J Cancer , 2021 , 148 ( 7 ): 1768 - 1777 . DOI: 10.1002/ijc.33430 http://doi.org/10.1002/ijc.33430

DVORSKÁ D , BRANÝ D , NAGY B , et al . Aberrant methylation status of tumour suppressor genes in ovarian cancer tissue and paired plasma samples [J ] . Int J Mol Sci , 2019 , 20 ( 17 ): 4119.

周俏苗 , 汪洪林 , 黄海燕 , 等 . MiR-124-3p靶向调控MAPK 14对子痫前期大鼠胎盘滋养层细胞增殖及侵袭的影响 [J ] . 中国比较医学杂志 , 2020 , 30 ( 6 ): 1 - 9 .

ZHOU Q M , WANG H L , HUANG H Y , et al . MiR-124-3p affects proliferation and migration in preeclampsia pathogenesis by targeting MAPK 14 [J ] . Chin J Comp Med , 2020 , 30 ( 6 ): 1 - 9 .

JIA X Q , WANG X , GUO X R , et al . MicroRNA-124: an emerging therapeutic target in cancer [J ] . Cancer Med , 2019 , 8 ( 12 ): 5638 - 5650 .

SHIMIZU T , SUZUKI H , NOJIMA M , et al . Methylation of a panel of microRNA genes is a novel biomarker for detection of bladder cancer [J ] . Eur Urol , 2013 , 63 ( 6 ): 1091 - 1100 . DOI: 10.1016/j.eururo.2012.11.030 http://doi.org/10.1016/j.eururo.2012.11.030

ADCOCK R , NEDJAI B , LORINCZ A T , et al . DNA methylation testing with S5 for triage of high-risk HPV positive women [J ] . Int J Cancer , 2022 , 151 ( 7 ): 993 - 1004 . DOI: 10.1002/ijc.34050 http://doi.org/10.1002/ijc.34050

Views

1267

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Association betweenGSTPl gene promoter methylation and prostate cancer

Detection of HIC1 promoter methylation in prostate cancer using MSP and BSP methods

The roles ofHPV16 E6,E7andE6/E7genes inSTK31promoter/exon1 methylation and expression levels in cervical cancer cell lines

ADAMTS9 protein downregulation induced by DNA promoter methylation could promote the progression of colorectal cancer

Related Author

罗建民

索晓慧

孙国锋

刘洪峰

李　静

牛广旭

张晓慧

朱明月

Related Institution

河北医科大学第二医院血液内科

河北省邯郸市中心医院肿瘤内科

河北省邯郸市中心医院病理科

河北省邯郸市中心医院血液内科

海南医学院海南省肿瘤发生和干预重点实验室

AI问答

⁰